Update 2020: Systemische Therapie des differenzierten und medullären Schilddrüsenkarzinoms

Zusammenfassung

Für das fortgeschrittene Radiojod-refraktäre differenzierte Schilddrüsenkarzinom (DTC) als auch für das progrediente medulläre Schilddrüsenkarzinom sind seit mehreren Jahren Tyrosinkinase-Inhibitoren (TKI) als wirksame Therapieoptionen zugelassen. Nicht zuletzt aufgrund des Toxizitätsprofiles der TKIs erfolgt deren Einsatz individualisiert und risikoadaptiert nach Ausschöpfen lokaler palliativer Therapieverfahren und wenn bei großer Tumormasse und/oder signifikantem Fortschreiten ein weiteres Abwarten nicht mehr vertretbar erscheint. Für das DTC gibt es zwei zugelassene Tyrosinkinaseinhibitoren, Lenvatinib und Sorafenib; für das MTC sind es ebenfalls zwei, Vandetanib und Cabozantinib. Hinzu kommen, vor allem in letzter Zeit, (relativ) selektive Inhibitoren einzelner Tyrosinkinasen (z. B. BRAF, MEK, NTRK, RET und mTOR), die im Rahmen von Studien oder im individuellen Heilversuch zur Verfügung stehen. Kürzlich erlangten zwei NTRK-Inhibitoren die europäische Zulassung und können bei Vorliegen einer NTRK-Fusion eingesetzt werden; leider ist diese Fusion jedoch relativ selten beim Schilddrüsenkarzinom zu finden.

In Summe sind die Nebenwirkungen der selektiven Inhibitoren meist geringer als die der bisher zugelassenen Medikamente, bei teils besserer, teils gleicher und teils etwas schlechterer Wirkung. Es steht zu erwarten, dass die selektiven Inhibitoren zukünftig das therapeutische Spektrum ergänzen werden. Grundvoraussetzung ist jedoch eine molekulare Analyse von Tumorgewebe mit Nachweis einer spezifischen Veränderung im Sinne eines „drugable target“. Um eine optimale individuelle Therapieplanung unter Berücksichtigung aller möglichen Therapieoptionen, inklusive Einschluss in klinische Studien, zu gewährleisten, sollten Patienten mit fortgeschrittenem MTC oder Radiojod-refraktären DTC interdisziplinär an spezialisierten Zentren (mit-)betreut werden.

Abstract

Since several years, tyrosine kinase inhibitors (TKI) have been approved as effective therapy options for advanced radiojodine-refractory differentiated thyroid carcinoma (DTC) and for progressive medullary thyroid carcinoma. Not only because of the toxicity profile of the TKIs, their use should be applied individualized and risk-adapted after exhausting local palliative therapy procedures and if, in the case of large tumor mass and/or significant progression, it is no longer justifiable to wait and watch. There are two approved tyrosine kinase inhibitors for DTC, lenvatinib and sorafenib; there are also two for MTC, vandetanib and cabozantinib. In addition, recently, there have been (relatively) selective inhibitors of individual tyrosine kinases (e. g. BRAF, MEK, NTRK, RET and mTOR) introduced, which are available in studies or in compassionate use programs. Two NTRK inhibitors have recently received European approval and can be used if there is an NTRK fusion; unfortunately, this fusion is relatively rare in thyroid cancer.

In general, the side effects of the selective inhibitors are usually less than those of the previously approved TKIs, with partly better, partly comparable and partly little poorer effect. It is expected that the selective inhibitors will complement the therapeutic spectrum in the future. The basic requirement, however, is a molecular analysis of tumor tissue with evidence of a specific mutation in the sense of a „drugable target“. In order to ensure optimal individual therapy planning considering all possible therapy options, including inclusion in clinical studies, patients with advanced MTC or radiojodine-refractory DTC should be (inter) disciplinarily discussed at specialized centers.

Schlüsselwörter

Tyrosinkinaseinhibitor - systemische Therapie - selektiver Inhibitor - differenziertes Schilddrüsenkarzinom - medulläres Schilddrüsenkarzinom

Keywords

Tyrosinkinaseinhibitor - systemic therapy - selective inhibitor - differentiated thyroid cancer - medullary thyroid cancer

Publikationsverlauf

Artikel online veröffentlicht:
21. September 2020

• Literatur

• 1 Lim H, Devesa SS, Sosa JA. et al. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA 2017; 317: 1338-1348
• 2 Durante C, Haddy N, Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radiojodine therapy. The Journal of clinical endocrinology and metabolism 2006; 91: 2892-2899
• 3 Spitzweg C, Bible KC, Hofbauer LC. et al. Advanced radiojodine-refractory differentiated thyroid cancer: the sodium jodide symporter and other emerging therapeutic targets. The lancet Diabetes & endocrinology 2014; 2: 830-842
• 4 Kreissl MC, Janssen MJR, Nagarajah J. Current Treatment Strategies in Metastasized Differentiated Thyroid Cancer. J Nucl Med 2019; 60: 9-15
• 5 Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006; 107: 2134-2142
• 6 Fassnacht M, Kreissl MC, Weismann D. et al. New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther 2009; 123: 117-141
• 7 Kreissl MC, Jentzen W, Janssen M. et al. 124J/131J-Theranostik des Natrium-Jodid-Symporters beim Schilddrüsenkarzinom. Der Nuklearmediziner 2019; 42: 15-20
• 8 Brose MS, Nutting CM, Jarzab B. et al. Sorafenib in radioactive jodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014; 384: 319-328
• 9 Schlumberger M, Tahara M, Wirth LJ. et al. Lenvatinib versus placebo in radiojodine-refractory thyroid cancer. N Engl J Med 2015; 372: 621-630
• 10 Brose MS, Worden FP, Newbold KL. et al. Effect of Age on the Efficacy and Safety of Lenvatinib in Radiojodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial. J Clin Oncol 2017; 35: 2692-2699
• 11 Wells Jr SA, Robinson BG, Gagel RF. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30: 134-141
• 12 Kreissl MC, Bastholt L, Elisei R. et al. Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial. J Clin Oncol 2020;
• 13 Elisei R, Schlumberger MJ, Muller SP. et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013; 31: 3639-3646
• 14 Cabanillas ME, de Souza JA, Geyer S. et al. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial. J Clin Oncol 2017; 35: 3315-3321
• 15 Okamura R, Boichard A, Kato S. et al. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. JCO Precis Oncol 2018;
• 16 Drilon A, Laetsch TW, Kummar S. et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. The New England journal of medicine 2018; 378: 731-739
• 17 Doebele RC, Drilon A, Paz-Ares L. et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020; 21: 271-282
• 18 Waguespack SG, Drilon A, Farago AF. et al. Treatment of advanced TRK fusion thyroid cancer with larotrectinib. ETA; 2019
• 19 Liu SV, Macke LA, Colton BS. et al. Response to Entrectinib in Differentiated Thyroid Cancer With a ROS1 Fusion. JCO Precision Oncology 2017; 1-5
• 20 Romei C, Elisei R. RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma. Front Endocrinol (Lausanne) 2012; 3: 54
• 21 Taylor MH, Gainor JF, Hu MI-N. et al. Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers. Journal of Clinical Oncology 2019; 37: 6018-6018
• 22 Wirth LJ, Cabanillas ME, Sherman E. et al. Clinical activity of LOXO-292, a highly selective RET inhibitor, in patients with RET-altered thyroid cancers. Thyroid; 2018 Abstract 6
• 23 Falchook GS, Millward M, Hong D. et al. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid: official journal of the American Thyroid Association 2015; 25: 71-77
• 24 Shah MH, Wei L, Wirth LJ. et al. Results of randomized phase II trial of dabrafenib versus dabrafenib lus trametinib in BRAF-mutated paillary thyroid carcinoma. J Clin Oncol 2017; 35: 6022
• 25 Brose MS, Cabanillas ME, Cohen EE. et al. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive jodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol 2016; 17: 1272-1282
• 26 Daud A, Tsai K. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. The oncologist 2017; 22: 823-833
• 27 Hanna GJ, Busaidy NL, Chau NG. et al. Genomic Correlates of Response to Everolimus in Aggressive Radiojodine-refractory Thyroid Cancer: A Phase II Study. Clin Cancer Res 2018; 24: 1546-1553